Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection

Abstract

This study aimed to assess attitudes and potential barriers towards treatment in patients with hepatitis C virus (HCV) infection, comparing those with and without HIV coinfection. A cross-sectional survey of 82 HCV-infected adults with and without HIV was conducted in greater Los Angeles between November 2013 and July 2015. Overall, there were 53 (64.6%) with HIV coinfection, 20 (25.0%) with self-reported cirrhosis, and 22 (26.8%) with a history of prior HCV treatment. Of all, 93.2% wanted HCV treatment, but 45.9% were unwilling/unable to spend anything out of pocket, 29.4% were waiting for new therapies, and 23.5% were recommended to defer HCV treatment. HIV/HCV-coinfected patients were more likely to want treatment within one year (90.2% versus 68.2%, p = 0.02), more willing to join a clinical trial (74.5% versus 8.0%, p < 0.01), more willing to take medications twice daily (86.3% versus 61.5%, p = 0.01), and more likely to prefer hepatitis C treatment by an infectious diseases/HIV physician (36.7% versus 4.0%, p < 0.01). Of all, 77.1% of coinfected patients were willing to change antiretroviral therapy if necessary to treat HCV, but only 48.0% of patients were willing to take a medication if it had not been studied in HIV-positive patients. Treatment preferences differ between HIV/HCV-coinfected and HCV-monoinfected patients. Despite a strong willingness among the study cohort to start HCV treatment, other factors such as cost, access to medications, and provider reluctance may be delaying treatment initiation.

Keywords

Human immunodeficiency virus hepatitis C virus treatment barriers survey

Get full access to this article

View all access options for this article.

References

Armstrong

Wasley

Simard

et al.

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–714.

Denniston

Jiles

Drobeniuc

et al.

Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293–300.

Edlin

Eckhardt

Shu

et al.

Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62: 1353–1363.

Yehia

Schranz

Umscheid

et al.

The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE 2014; 9: e101554–e101554.

Kim

Onofrey

Church

. An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis 2013; 207: S1–S6.

Lin

Weinberg

Chung

. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis 2013; 207: S13–S18.

Xing

Klevens

et al.

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271–278.

Grebely

Oser

Taylor

et al.

Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013; 207: S19–S25.

Sulkowski

. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis 2013; 207: S26–S32.

10.

Cope

Glowa

Faulds

et al.

Treating hepatitis C in a Ryan White-funded HIV clinic: has the treatment uptake improved in the interferon-free directly active antiviral era?

AIDS Patient Care STDS 2016; 30: 51–55.

11.

Barua

Greenwald

Grebely

et al.

Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163: 215–223.

12.

Oramasionwu

Moore

Toliver

. Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review. AIDS Patient Care STDS 2014; 28: 228–239.

13.

Cachay

Hill

Wyles

et al.

The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. Bonino F, editor. PLoS ONE 2014; 9: e102883–e102883.

14.

Mendes-Correa

Martins

Tenore

et al.

Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil. Braz J Infect Dis 2010; 14: 237–241.

15.

Chen

T-Y

Jain

. Treatment of hepatitis C in HIV-infected patients: moving towards an era of all oral regimens. AIDS Patient Care STDS 2015; 29: 329–337.

16.

Papadopoulos

Manolakopoulos

Deutsch

et al.

Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. Eur J Gastroenterol Hepatol 2013; 25: 587–593.

17.

AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–954.

18.

Arends

Lieveld

Boeijen

et al.

Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms?

J Hepatol 2015; 63: 1254–1262.

19.

Chastain

Beekmann

Wallender

et al.

Hepatitis C management and the infectious diseases physician: a survey of current and anticipated practice patterns. Clin Infect Dis 2015; 61: 792–794.

20.

Cachay

Wyles

Hill

et al.

The impact of direct-acting antivirals in the hepatitis C-sustained viral response in human immunodeficiency virus-infected patients with ongoing barriers to care. Open Forum Infect Dis 2015; 2: ofv168–ofv168.

21.

Townsend

Petersen

Gordon

et al.

Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS 2016; 30: 261–266.